Latest News

Siponimod – new data in SPMS


Click here to take the SPMS survey

Siponimod, the selective sphingosine-1-phosphate (S1P) receptor modulator (S1P1,5), produces a sustained reduction in worsening disability for up to five years in patients with secondary-progressive MS (SPMS), according to data submitted to the American Academy of Neurology annual meeting (Kappos et al. AAN 2020; abstract S40.003).

Read More


FDA approves ozanimod in MS


The U.S. Food and Drug Administration has approved ozanimod (Zeposia) for the treatment of relapsing forms of MS, including clinically isolated syndrome (CIS), RRMS and active SPMS. The drug was developed by Receptos, then acquired by Celgene before Celgene was acquired in turn by Bristol-Myers Squibb. Ozanimod was submitted for review by Health Canada in December 2019. Read More